Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2018, Article ID 9679287, 4 pages
https://doi.org/10.1155/2018/9679287
Case Report

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis

1Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
2Division of Gastroenterology, Hepatology and Parenteral Nutrition, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

Correspondence should be addressed to David Padua; ude.alcu.tendem@audapd

Received 21 November 2017; Accepted 18 January 2018; Published 15 February 2018

Academic Editor: Hirotada Akiho

Copyright © 2018 Dean Ehrlich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Secukinumab [package insert]. Novartis Pharmaceuticals, East Hanover, New Jersey, USA, 2015, https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf.
  2. W. Hueber, B. E. Sands, S. Lewitzky et al., “Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blindplacebo-controlled trial,” Gut, vol. 61, no. 12, pp. 1693–1700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Baeten, J. Sieper, J. Braun et al., “Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis,” The New England Journal of Medicine, vol. 373, no. 26, pp. 2534–2548, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Baraliakos, A. Kivitz, A. Deodhar et al., “THU0397Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from a phase 3 extension trial (MEASURE 1),” in Proceedings of the Annual European Congress of Rheumatology, 14–17 June, 2017, pp. 357.2–358. View at Publisher · View at Google Scholar
  5. S. Schreiber, B. Sands, A. Deodhar et al., “OP0113No Increased Incidence of Inflammatory Bowel Disease among Secukinumab-Treated Patients with Moderate To Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies,” Annals of the Rheumatic Diseases, vol. 75, no. Suppl 2, pp. 97-98, 2016. View at Publisher · View at Google Scholar
  6. F. Kerdel and M. Zaiac, “An evolution in switching therapy for psoriasis patients who fail to meet treatment goals,” Dermatologic Therapy, vol. 28, no. 6, pp. 390–403, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. U. Mrowietz, E. M. G. J. De Jong, K. Kragballe et al., “A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 28, no. 4, pp. 438–453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Hirten, R. S. Longman, B. P. Bosworth, A. Steinlauf, and E. Scherl, “Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease,” American Journal of Gastroenterology, vol. 110, no. 12, pp. 1737-1738, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. B. E. Sands, R. Kozarek, J. Spainhour et al., “Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab,” Inflammatory Bowel Diseases, vol. 13, no. 1, pp. 2–11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Ogawa, A. Andoh, Y. Araki, T. Bamba, and Y. Fujiyama, “Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice,” Clinical Immunology, vol. 110, no. 1, pp. 55–62, 2004. View at Publisher · View at Google Scholar · View at Scopus